Angew Chem Int Ed Engl
. 2021 Jan 19.
doi: 10.1002/anie.202015362. Online ahead of print.
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine
Sonia Jangra 1 , Jana De Vrieze 2 , Angela Choi 1 , Raveen Rathnasinghe 1 , Gabriel Laghlali 1 , Annemiek Uvyn 3 , Simon Van Herck 4 , Lutz Nuhn 5 , Kim Deswarte 6 , Zifu Zhong 2 , Niek Sanders 7 , Stefan Lienenklaus 8 , Sunil David 9 , Shirin Strohmeier 1 , Fatima Amanat 1 , Florian Krammer 1 , Hamida Hammad 6 , Bart N Lambrecht 6 , Lynda Coughlan 1 , Adolfo Garc?a-Sastre 1 , Bruno de Geest 10 , Michael Schotsaert 1
Affiliations
- PMID: 33464672
- DOI: 10.1002/anie.202015362
Abstract
The search for vaccines that protect from severe morbidity and mortality as a result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19) is a race against the clock and the virus. Here we describe the use of a novel amphiphilic imidazoquinoline (IMDQ-PEG-CHOL) TLR7/8 adjuvant, consisting of an imidazoquinoline conjugated to the chain end of a cholesterol-poly(ethylene glycol) macromolecular amphiphile. This amphiphile is water soluble and exhibits massive translocation to lymph nodes upon local administration, likely through binding to albumin, affording localized innate immune activation and a dramatic reduction in systemic inflammation. The adjuvanticity of IMDQ-PEG-CHOL was validated in the context of a licensed vaccine setting (i.e. the quadrivalent influenza vaccine) and an experimental trimeric recombinant SARS-CoV-2 spike protein vaccine, showing robust IgG2a and IgG1 antibody titers in mice that could neutralize viral infection in vitro and in vivo in a mouse model.
Keywords: vaccines, amphiphiles, innate immunity, SARS-CoV-2, COVID-19.